NovoCure (NVCR) Change in Cash (2014 - 2026)

NovoCure has disclosed Change in Cash across 13 years of filings, most recently posting -$6.1 million for Q1 2026.

• Change in Cash for Q1 2026 came in at -$6.1 million, up 83.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.1 million (up 90.21% YoY), and the FY2025 annual result was -$62.7 million, up 18.0% from the prior year.
• Change in Cash came in at -$6.1 million for Q1 2026 at NovoCure, up from -$241.2 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $214.8 million in Q1 2024 to a low of -$288.9 million in Q2 2024.
• The 5-year median for Change in Cash is -$6.1 million (2026), against an average of -$6.6 million.
• Across the five-year window, Change in Cash soared 2213.65% in 2024 and plunged 944.14% in 2025, its largest moves.
• NovoCure's Change in Cash stood at -$128.2 million in 2022, then soared by 167.12% to $86.1 million in 2023, then slumped by 126.85% to -$23.1 million in 2024, then slumped by 944.14% to -$241.2 million in 2025, then surged by 97.49% to -$6.1 million in 2026.
• The last three Change in Cash figures came in at -$6.1 million (Q1 2026), -$241.2 million (Q4 2025), and $192.5 million (Q3 2025), per Business Quant data.